In a statement, South Korean LegoChen Biosciences and UK’s Iksuda Therapeutics confirmed that the companies have entered into a multi-target research collaboration and license agreement. As part of the agreement, Legochem Biosciences grants Iksuda access to the next-generation Pyrrolobenzodiazepine (PBDs) prodrug payload and proprietary linker to discover and advance ADCs for difficult-to-treat tumors

Iksuda gains limited rights to LCB’s ADC technology, ConjuALL, including LCB’s tumor-selectively activated payloads as well as its proprietary linker and conjugation platform, to research, develop and commercialize targeted anti-cancer therapeutics. Based on the agreement Iksuda has the right to use the LCB technology to develop therapeutics directed to up to three undisclosed targets.

The ConjuAll technology platform creates ADCs by connecting antibodies, linkers, and efficient toxin release technologies. The Korean company began developing the technology between 2009 and 2010, completed the linker technology in 2010 and the toxin release technology eight years later.

Milestone payments
As part of the global research collaboration and license agreement, Legochem is expected to receive in up to US $ 407 million from development, regulatory, and commercial milestone payments, as well as royalties on the sales of any resulting ADC products.

Advertisement #3 
Axplora
 
Dave Simpson Ph.D, is Chief Executive Office and co-founder of Iksuda Therapeutics (formally Glythera), a pre-clinical stage company developing Antibody-drug Conjugates or ADCs for difficult to treat solid tumors.
Dave Simpson Ph.D, is Chief Executive Office and co-founder of Iksuda Therapeutics (formally Glythera), a pre-clinical stage company developing Antibody-drug Conjugates or ADCs for difficult to treat solid tumors.

The agreement allows Iksuda to build on its already impressive portfolio of ADC assets and provides more scope to match the best ADC components to create best-in-class drugs according to the target antigen and tumor. Through this partnership, Iksuda can leverage LCB’s next-generation linker and payload platform and, through its Team’s expertise and proven capability in ADC development, will advance ADCs to the clinic as quickly as possible.

“Based on this partnership, we’ll plan to advance antibody-drug conjugates developed as a result of this partnership to the clinical stage as quickly as possible,” noted David Simpson, Chief Executive Officer of Iksuda.

“Our collaboration allows us to leverage LCB’s next-generation linker and payload platform, and combining it with our expertise and capabilities in ADC development will enable success,” Simpson added

“The goal is to demonstrate the competitiveness of Legochem Bio in human trials in an efficient way by applying our ADC platform to Iksuda’s pipelines,” concluded Yong-Zu Kim, Chief Executive officer of Legochem.

LCB73 – Licensing Agreement
As part of the agreement, Iksuda also gains worldwide rights to LCBs anti-CD19 ADC LCB73 for development and commercialization in B-cell cancers.

Preclinical data of LCB73 along with clinical outcomes of other CD19-targeted therapies suggest that this ADC represents an effective option for the treatment of various B-cell hematological cancers including diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma – thus matching Iksuda’s goal to develop best-in-class ADCs for hard-to-treat cancers with high unmet need.

Iksuda plans to advance LCB73 into the clinic in the most efficient manner, utilizing its extensive UK and US-based ADC expertise to drive pre-clinical and clinical development activities.

Advertisement #4